Acute myeloid leukemia (t-AML) is one of the worst adverse events of mitoxantrone treatment, but the exact risk in multiple sclerosis (MS) patients is not yet known. We describe a case wherein the patient developed t-AML 11 months after mitoxantrone had been discontinued. The patient was treated by polychemotherapy and autologous bone marrow transplantation with complete recovery of t-AML and stabilization of the neurological disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10072-008-0934-1 | DOI Listing |
Publication Analysis
Top Keywords
acute myeloid
8
myeloid leukemia
8
mitoxantrone treatment
8
multiple sclerosis
8
leukemia induced
4
induced mitoxantrone
4
treatment aggressive
4
aggressive multiple
4
sclerosis acute
4
leukemia t-aml
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!